REGULUS Trial
Phase 2
62
about 4.1 years
18+
1 site in CA
What this study is about
This trial is testing a new way to deliver radiation therapy called MRI-guided adaptive SABR. It uses imaging scans to plan and adjust the treatment during one session for patients with liver cancers.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive MRI-guided adaptive stereotactic ablative body radiotherapy (SABR)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: 1-year Overall Survival (OS)
Secondary: Change from Baseline in COST-FACIT Total Score up to 1 Year Post-SABR, Change from Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life Score up to 1 Year Post-SABR, Change from Baseline in FACT-Hep Total Score up to 1 Year Post-SABR, Rate of Grade ≥ 2 Chest Wall Toxicity, Rate of Grade ≥ 2 Gastrointestinal (GI) Adverse Events
radiation
Gastroenterology